The recent incorporation of Au chemistry in the bioorthogonal toolbox has opened up new opportunities to deliver biologically independent reactions in living environments. Herein we report that the O-propargylation of the hydroxamate group of the potent HDAC inhibitor panobinostat leads to a vast reduction of its anticancer properties (>500-fold). We also show that this novel prodrug is converted back into panobinostat in the presence of Au catalysts in vitro and in cell culture.
Keywords: Anticancer therapies; Bioorthogonal catalysis; Gold nanoparticles; HDAC inhibitors.
Copyright © 2021 Elsevier Ltd. All rights reserved.